about
The average body surface area of adult cancer patients in the UK: a multicentre retrospective studyRole of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitorsInhibition of OATP-1B1 and OATP-1B3 by tyrosine kinase inhibitorsThe tumor microenvironment and strategies to improve drug distributionIntegrating in vitro ADMET data through generic physiologically based pharmacokinetic models.Myeloid toxicity of cancer treatment.Frontiers in cancer nanomedicine: directing mass transport through biological barriersChemotherapy during pregnancy: pharmacokinetics and impact on foetal neurological developmentMulti-stage delivery nano-particle systems for therapeutic applications5-Fluorouracil derivatives: a patent review.Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes.Telodendrimer nanocarrier for co-delivery of paclitaxel and cisplatin: A synergistic combination nanotherapy for ovarian cancer treatment.Pharmacogenetics of intravenous and oral busulfan in hematopoietic cell transplant recipients.Minichromosome Maintenance Protein 7 is a potential therapeutic target in human cancer and a novel prognostic marker of non-small cell lung cancerA Systems Biology Approach in Therapeutic Response Study for Different Dosing Regimens-a Modeling Study of Drug Effects on Tumor Growth using Hybrid SystemsResistance to cancer chemotherapy: failure in drug response from ADME to P-gp.HEY1 Leu94Met gene polymorphism dramatically modifies its biological functionsInterindividual differences in phytochemical metabolism and dispositionAcute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy.Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics.The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis.Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects.Dynamical modeling of drug effect using hybrid systems.Drug metabolism by tumours: its nature, relevance and therapeutic implications.A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours.Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751.Feasibility of spatial frequency domain imaging (SFDI) for optically characterizing a preclinical oncology model.Gender and interindividual variability in pharmacokinetics.Effects of herbal products on the metabolism and transport of anticancer agents.Therapeutic drug monitoring in cancer chemotherapy.Metabolic and toxicological considerations of botanicals in anticancer therapy.Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy?5-Fluorouracil derivatives: a patent review (2012 - 2014).Molecular mechanisms for tumor resistance to chemotherapy.Active targeting of chemotherapy to disseminated tumors using nanoparticle-carrying T cells.Praziquantel for Schistosomiasis: Single-Drug Metabolism Revisited, Mode of Action, and Resistance.Meta-analysis of inter-patient pharmacokinetic variability of liposomal and non-liposomal anticancer agents.Separation and simultaneous quantification of nine furanocoumarins from Radix Angelicae dahuricae using liquid chromatography with tandem mass spectrometry for bioavailability determination in rats.Cyclodextrin-based targeting strategies for tumor treatment.Repurposing itraconazole for the treatment of cancer.
P2860
Q21142666-EA58F1C9-9426-4B1F-A1FE-8D7527726E24Q28236180-0AC13112-693E-4359-9B66-C270EA1CAF56Q28239708-26AE1AE0-0485-4678-9C99-5E092F31BFD2Q28384148-55CC3393-E179-48FE-A53D-DF913F584F01Q31049476-3526C72F-0ED0-4FD4-9E75-93F27C57D46BQ33416472-97745C36-90AA-47E2-86D0-2AD8FB322BFAQ33746335-365D3D78-9A61-4086-B66C-E1A7C3472410Q33860406-4D17F1AA-8B0E-4392-8FA7-72E74F204D94Q34166491-B7C5E644-5F70-472E-B731-EEB3BF0F7959Q34253978-7540C50B-B8EA-4E31-9BC8-62419C1F1588Q34612932-9C7C3A45-6C1F-40D8-9208-B2A189AA8494Q35032561-305E294D-FCF3-4B7A-BF8A-EB17871734CEQ35053340-F7726CA2-E57B-4530-BC9F-2CF089342C5CQ35074445-C03EDECB-DD62-410E-A1C8-D1D315655A63Q35817902-E687FA7B-490F-4415-9BFD-D4BD2C7D21DDQ35852614-53F4F6A1-CA24-4665-B73D-0F1826A419F4Q36054564-5739FFBF-AD53-43F0-BFBE-F1E9C0876C10Q36148997-C4CF1903-B78A-4EA1-A96F-C2FCC64F3F03Q36402208-FAF829EA-9A49-4CC8-934E-114F503762CFQ36402212-8BC94A40-468C-4886-88C5-ADB4C06583F8Q36664974-87151532-73E3-49B0-88FD-F03CA042E1ADQ36792665-1627CEFD-B4D9-458B-A9CF-E5314CCD40CCQ36803684-816B5B56-D7C9-4244-95E0-BAD9EF9E9807Q37008879-E9AD6264-4463-4437-B8CF-D0238401CA4CQ37317560-6942DEE6-7877-494C-993D-457995F22C51Q37382760-A8E5AB51-DCE4-495D-8533-936ADC2DB3F9Q37404430-A93B221A-AF7C-489C-8907-EE8C5F8A3770Q37550556-E26D0936-A310-4D4E-B67B-DBA3215A6F62Q37779320-88EE9650-3AB8-47DD-9277-7D99D0BBCD1DQ37810220-91607D60-7ECE-4A0C-ACAA-277D05B989ACQ38006050-6CFA44BD-74F3-48F8-83FE-232A22EC862DQ38022125-4EC0AEBC-FE12-4A0F-8E59-88EF5A49DCF6Q38545641-CD2AC524-4A0C-4606-8BE8-288DDE072D00Q38813053-DC8A71B8-7F68-441D-B552-671B9B883FA8Q38865261-CFCFAA12-E129-4BDB-AD88-E5DC7BF57E23Q39164325-296848C9-59C7-4751-B584-B5E62385FAE4Q39377012-3421D8EE-5705-482C-A081-94DB3575E07CQ40397923-CA8EC1C2-12CA-4487-98A5-41FC59C22DBCQ41195619-4D4FD00E-BC8A-480D-8662-085598DE5C9EQ41613808-29DA4D72-B315-4C11-B4F8-D729F07F9C20
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Pharmacokinetic variability of anticancer agents.
@ast
Pharmacokinetic variability of anticancer agents.
@en
type
label
Pharmacokinetic variability of anticancer agents.
@ast
Pharmacokinetic variability of anticancer agents.
@en
prefLabel
Pharmacokinetic variability of anticancer agents.
@ast
Pharmacokinetic variability of anticancer agents.
@en
P2860
P356
P1476
Pharmacokinetic variability of anticancer agents.
@en
P2093
Gonzalo Gomez-Abuin
Samir D Undevia
P2860
P2888
P304
P356
10.1038/NRC1629
P407
P577
2005-06-01T00:00:00Z